Steroids in COVID-19: An overview
Kshitij Chatterjee, Chao-Ping Wu, Abhishek Bhardwaj, Matthew Siuba
Abstract
Most antiviral or immunomodulatory therapies investigated for use in patients with COVID-19 have failed to show any mortality benefit. Similar to the previous pandemics caused by respiratory viruses, the role and benefit of corticosteroids has been under debate in COVID-19-related pulmonary disease. In this consult, we discuss the evidence regarding the efficacy of corticosteroid use in hospitalized patients with COVID-19, including data from the first randomized controlled trial on this subject.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Pandemic2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineRandomized controlled trialMEDLINEDiseaseVirologyInternal medicineInfectious disease (medical specialty)OutbreakPolitical scienceLawCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Thermal Regulation in Medicine